Biotech · Private company
Shanghai Henlius Biotech
Track this companyFree. Adds Shanghai Henlius Biotech to your Dealase workspace and tells you when its record changes.
Clinical trials118 recruiting or active
Pipeline programs27From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline27
- Atezolizumab + chemotherapy (carboplatin-etoposide)Phase 3 · Extensive Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CapecitabinePhase 3 · Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- carboplatin and nab paclitaxelPhase 3 · Squamous Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- carboplatin/cisplatin-etoposidePhase 3 · Limited-Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX04-OPhase 3 · Age Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- HLX10Phase 3 · Squamous Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX10Phase 3 · Limited-Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX22Phase 3 · Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 3 · Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- Prophylactic Cranial Irradiation (PCI)Phase 3 · Limited-Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ranibizumabPhase 3 · Age Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Serplulimab + chemotherapy (carboplatin-etoposide)Phase 3 · Extensive Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Thoracic radiotherapyPhase 3 · Limited-Stage Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 3 · Gastroesophageal-junction CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX43 DOSE 1 (2.0 mg/kg)Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX43 DOSE 2 (2.5 mg/kg)Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX10Phase 1 · Advanced/Metastatic Malignant Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- HLX13Phase 1 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- HLX15-SC-RdPhase 1 · Multiple Myeloma (MM)ClinicalTrials.gov · fetched Nov 12, 2026
- HLX17Phase 1 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HLX23Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- HLX43Phase 1 · Advanced/Metastatic Malignant Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- OPDIVOPhase 1 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- US-DARZALEX FASPRO®-RdPhase 1 · Multiple Myeloma (MM)ClinicalTrials.gov · fetched Nov 12, 2026
- US-sourced Keytruda®Phase 1 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- YervoyPhase 1 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaPHASE1 · RECRUITING · started May 25, 2026ClinicalTrials.gov NCT07477587 · fetched Nov 12, 2026
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaPHASE1 · RECRUITING · started Nov 25, 2025ClinicalTrials.gov NCT07176650 · fetched Nov 12, 2026
- A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 26, 2025ClinicalTrials.gov NCT07160335 · fetched Nov 12, 2026
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)PHASE2 · RECRUITING · started Jun 9, 2025ClinicalTrials.gov NCT06907615 · fetched Nov 12, 2026
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerPHASE3 · RECRUITING · started Nov 22, 2024ClinicalTrials.gov NCT06532006 · fetched Nov 12, 2026
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsPHASE1 · ENROLLING_BY_INVITATION · started Nov 24, 2023ClinicalTrials.gov NCT06115642 · fetched Nov 12, 2026
- To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 18, 2022ClinicalTrials.gov NCT05468489 · fetched Nov 12, 2026
- A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid TumorPHASE1 · WITHDRAWN · started Jul 18, 2022ClinicalTrials.gov NCT04797468 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerPHASE3 · ACTIVE_NOT_RECRUITING · started May 17, 2022ClinicalTrials.gov NCT05353257 · fetched Nov 12, 2026
- A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDPHASE3 · COMPLETED · started Jul 1, 2021ClinicalTrials.gov NCT04740671 · fetched Nov 12, 2026
- A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCPHASE3 · UNKNOWN · started Aug 14, 2019ClinicalTrials.gov NCT04033354 · fetched Nov 12, 2026